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An evaluation of DnA 
Methyltransferase 1 (DNMT1) 
Single nucleotide polymorphisms 
and chemotherapy-Associated 
cognitive impairment: A 
prospective, Longitudinal Study
Alexandre chan1,2,3, Angie Yeo1, Maung Shwe1, chia Jie tan  1, Koon Mian foo4, pat chu5, 
chiea chuen Khor  6,7 & Han Kiat Ho  1
Strong evidence suggests that genetic variations in DNA methyltransferases (DNMTs) may alter the 
downstream expression and DNA methylation patterns of neuronal genes and influence cognition. This 
study investigates the association between a DNMT1 polymorphism, rs2162560, and chemotherapy-
associated cognitive impairment (CACI) in a cohort of breast cancer patients. This is a prospective, 
longitudinal cohort study. From 2011 to 2017, 351 early-stage breast cancer patients receiving 
chemotherapy were assessed at baseline, the midpoint, and the end of chemotherapy. DNA was 
extracted from whole blood, and genotyping was performed using Sanger sequencing. Patients’ self-
perceived cognitive function and cognitive performance were assessed at three different time points 
using FACT-Cog (v.3) and a neuropsychological battery, respectively. The association between DNMT1 
rs2162560 and cognitive function was evaluated using logistic regression analyses. Overall, 33.3% of 
the patients reported impairment relative to baseline in one or more cognitive domains. Cognitive 
impairment was observed in various objective cognitive domains, with incidences ranging from 7.2% 
to 36.9%. The DNMT1 rs2162560 A allele was observed in 21.8% of patients and this was associated 
with lower odds of self-reported cognitive decline in the concentration (OR = 0.45, 95% CI: 0.25–0.82, 
P = 0.01) and functional interference (OR = 0.48, 95% CI: 0.24–0.95, P = 0.03) domains. No significant 
association was observed between DNMT1 rs2162560 and objective cognitive impairment. This is the 
first study to show a significant association between the DNMT1 rs2162560 polymorphism and CACI. 
our data suggest that epigenetic processes could contribute to cAci, and further studies are needed to 
validate these findings.
Chemotherapy-associated cognitive impairment (CACI) is highly prevalent among cancer patients receiving 
chemotherapy1–3. Reports have shown that CACI negatively affects patients’ social functioning and quality of 
life3,4. The exact mechanism underlying CACI has yet to be elucidated. However, genetic factors are known to 
contribute to CACI5–8.
Epigenetic modifications such as DNA methylation can modify intermediate neuronal gene expres-
sion, leading to changes in cognitive performance9. DNA methylation is catalyzed by DNA methyltransferase 
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(DNMT) enzymes and involves the addition of a methyl group to the 5′-position of cytosine bases, primarily 
at cytosine-phosphate-guanine (CpG) dinucleoside sites, which results in gene silencing10. In mammalian cells, 
DNMT1 is the most abundant form of DNA methyltransferases. It is primarily responsible for maintaining meth-
ylation and has a higher affinity for hemimethylated DNA11. DNMT-mediated DNA methylation regulates multi-
ple aspects of neuronal development and function, with important roles in learning and memory12–14. Clinically, 
the dysregulated expression or aberrant function of DNMT1 could affect neurocognitive function by altering 
the methylation patterns of cognitive gene targets15,16. Recently, a prospective study reported cognitive decline 
is associated with DNA methylation of leukocytes in breast cancer patients receiving chemotherapy, providing 
evidence of epigenetic links to CACI17.
The extent of methylation is controlled by the expression and function of DNMT1, which can be altered by 
single nucleotide polymorphisms (SNPs) situated within its genetic code18. DNMT SNPs have been studied in 
Alzheimer’s disease and schizophrenia19,20. However, DNMT SNPs have not been investigated in CACI. Using 
a candidate gene approach, we identified the DNMT1 SNP rs2162560 from the literature19,20 and evaluated its 
association with CACI in a cohort of breast cancer patients. We hypothesize that carriers of the A allele of the 
rs2162560 polymorphism have increased DNA methylation activity that protects them from CACI.
Methods
Study design. This multicenter, prospective, longitudinal cohort study was conducted in Singapore between 
2011 and 2017. This study was approved by the SingHealth Centralized Institutional Review Board. Written 
informed consent was obtained from all participants. All experiments were performed in accordance with rele-
vant guidelines and regulations.
Participants. Patients were eligible to participate in this study if they fulfilled the following inclusion cri-
teria: (i) at least 21 years old, (ii) diagnosed with stage I-IIIA breast cancer, (iii) scheduled for four cycles of 
anthracycline- or taxane-based chemotherapy, (iv) no history of chemotherapy or radiotherapy, and (v) read and 
understand English or Mandarin. Patients who were (i) symptomatically ill, (ii) diagnosed with brain metastasis 
or any neuropsychiatric illness that may cause cognitive impairment, or (iii) physically or mentally incapable of 
giving written informed consent were excluded.
Study procedure. The first time point (T1) occurred at baseline before the initiation of chemotherapy. 
The second time point (T2) was timed at 6 weeks after T1 and coincided with the first day of the third cycle of 
chemotherapy. The third time point (T3) was 12 weeks after T1 when the primary chemotherapy was completed. 
Overall, the approximate duration between each time point was 6 weeks. Patients completed both objective and 
subjective neuropsychological assessments and self-reported questionnaires to assess their health-related quality 
of life, fatigue, and anxiety. All tools were available in English and Chinese and were administered by trained 
bilingual interviewers.
Assessment tools. Subjective cognitive functioning was assessed using the Functional Assessment of 
Cancer Therapy – Cognitive Function (FACT-Cog) version 3, which is a patient-reported questionnaire that 
measures self-perceived cognitive impairment21. It evaluates the cognitive domains of mental acuity, concen-
tration, memory, functional interference, verbal fluency, and multitasking. The domain scores are calculated by 
summing the individual domain items, and the FACT-Cog summation score is obtained by adding all item scores 
together. The English and Chinese versions of the FACT-Cog used in this study were previously validated and 
have demonstrated equivalence and reliability22.
Objective cognitive function was initially assessed using Headminder. As Headminder was commercially 
discontinued in 2014, the Cambridge Neuropsychological Test Automated Battery (CANTAB, Cambridge 
Cognition Ltd., UK) was used for objective cognitive assessment for the remainder of the study. Both neuropsy-
chological tests are language-independent and computer-based. For both batteries, four cognitive domains were 
assessed: processing speed, response speed, memory, and attention. The specific measures used by Headminder 
and CANTAB as neuropsychological assessments are described in Supplementary Table 1. These tests have been 
validated and show sensitivity in capturing alterations in neuropsychological performance in the four cognitive 
domains23,24.
Anxiety, cancer-related fatigue, and insomnia are known confounders of cognition and were assessed by 
validated patient-reported questionnaires – the Beck Anxiety Inventory (BAI)25, the Brief Fatigue Inventory 
(BFI)26, and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
C-30 (EORTC QLQ-C30)27, respectively.
Defining cognitive impairment. The overall impairment in self-perceived cognitive function was defined 
as a reduction in the FACT-Cog summation score by ≥10.6 points during (T2) or after chemotherapy (T3) com-
pared with the baseline value. This reduction is based on the minimal clinically important difference (MCID) that 
we previously established as clinically significant28. The FACT-Cog MCID range is in line with a change of 5–10% 
in the EORTC-QLQ-C30 scales, which is proposed to be the minimal clinically significant change. For individual 
cognitive domains, patients were considered to be experiencing clinically significant cognitive impairment if their 
domain scores at T2 or T3 were ≥15% lower than their baseline score8.
Reliable change index (RCI) scores were calculated to assess changes in objective cognition. RCI was com-
puted by calculating the difference of Headminder or CANTAB scores between baseline and T2 or T3, sub-
tracting the mean practice effect extrapolated from a normative group and dividing by the standard error of 
difference. The RCI for both Headminder and CANTAB were calculated using two separate reference groups 
(Supplementary Table 2). Patients were classified as having impairment in each of the cognitive domains if the 
RCI score was ≤−1.529.
3Scientific RepoRtS |         (2019) 9:14570  | https://doi.org/10.1038/s41598-019-51203-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Genotyping. Upon recruitment, 10 mL of whole blood was drawn from each participant into an ethylenedi-
aminetetraacetic acid (EDTA) tube. The samples were centrifuged at 2500 rpm for 10 minutes within 30 minutes 
of collection. The buffy coat was drawn and stored at −80 °C until analysis. Genomic DNA was extracted from the 
buffy coat using the QIAamp DNA Blood Mini Kit (Qiagen) according to the manufacturer’s protocol. The regions 
containing polymorphisms were amplified by polymerase chain reaction (PCR) using the following optimized 
primers: 5′-AAGCACAAAGGCAGGTTCGC-3′ (forward) and 5′-GTGCCCAGCTGCAAAGTGTT-3′ (reverse). 
Genotyping was performed without knowledge of clinical outcomes by AITbiotech Pte Ltd. (Singapore).
Statistical analysis. Descriptive statistics were used to summarize the demographic and clinical charac-
teristics of the patients. Differences in the demographic data and questionnaire scores between patients with 
and without cognitive impairment were compared using the independent-sample t-test if normally distributed. 
The Mann-Whitney U-test was used to compare non-normally distributed continuous and ordinal data. The 
chi-squared test was used to identify differences in categorical demographic data between the two groups. The 
Friedman test was used to evaluate changes in questionnaire and neuropsychological test scores across the three 
time points.
Genotype and allele frequencies were checked for deviation from the Hardy-Weinberg equilibrium using 
the chi-squared test with one degree of freedom. Binary logistic regression analysis assuming a dominant model 
was carried out to evaluate associations between the SNP of interest and cognitive function while adjusting for 
ethnicity and documented confounders of CACI (age, fatigue, menopausal status, chemotherapy regimen, and 
education level)30,31. In addition, anxiety, insomnia and brain-derived neurotrophic factor (BDNF) rs6265 poly-
morphism status were incorporated as confounders in the analysis model for subjective cognitive impairment as 
they are associated with self-reported cognitive impairment in breast cancer patients3,8. Univariate analysis was 
conducted and any variables that achieved P ≤ 0.1 were included in the logistic regression model. Anxiety (total 
BAI score), fatigue (total BFI score), and insomnia (EORTC QLQ-C30 insomnia score) scores corresponding 
to the time point at which cognitive impairment occurred were used in the logistic regression model. Using the 
median age as a cut-off, a subgroup analysis was conducted to evaluate whether similar genetic associations were 
observed in younger patients (below the median age of the cohort).
Results were reported as odds ratios (ORs) and 95% confidence intervals (CIs). Only cases with complete 
genetic and clinical information were included in the analysis. Statistical analyses were carried out using IBM’s 
Statistical Package for the Social Sciences (SPSS version 20) with P ≤ 0.05 considered as statistically significant.
Results
Patient demographics. A total of 425 patients were recruited, of which 351 patients were included in the 
final analysis (Fig. 1). The mean age (±SD) was 51.2 ± 9.1 years. Patients were predominantly Chinese (81.2%), 
and 85.2% had received at least high school education. Over half (59.8%) were diagnosed with stage II breast 
cancer and almost all (95.6%) had a baseline Eastern Cooperative Oncology Group (ECOG) score of 0, indicating 
an ambulatory status without restrictions on daily activities. Two-thirds (64.7%) of the patients received an anth-
racycline-based chemotherapy regimen. Among patients who completed objective neuropsychological tests, 125 
(50.6%) were assessed using Headminder, while 122 (49.4%) were assessed using CANTAB. The demographic 
and clinical characteristics of the participants receiving Headminder and CANTAB were similar (Table 1). There 
was a statistically significant reduction in the FACT-Cog summation score as well as the domain scores over 
time (Supplementary Table S3) with approximately one-third of the patients experiencing clinically significant 
Eligible participants consented for study, N = 425 
Withdrawn from study, N = 60 
Did not provide blood sample, N = 9 
Incomplete covariate data, N = 4
Subjective Objective 
FACT-Cog, N = 352 Headminder, N = 157 CANTAB, N = 195 
Included in analysis, N = 352 
Did not complete, N = 1 Did not receive, N = 9 Did not complete, N = 23 
Did not receive, N = 57 
Did not complete, N = 16 
Analysed for FACT-Cog, 
N = 351 
Analysed for Headminder, 
N = 125 
Analysed for CANTAB,  
N = 122 
Figure 1. Study flow diagram.
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decline in self-perceived cognitive function (Table 2). Cognitive impairment was also observed in various objec-
tive cognitive domains, with incidences ranging from 7.2% to 36.9% (Table 2). Patients assessed with Headminder 
showed stable to improved cognitive function over time in 3 out of 4 cognitive domains. In contrast, improvement 
of cognitive function over time was only observed in 1 out of 4 cognitive domains among patients assessed with 
CANTAB (Supplementary Table S3).
Demographic and clinical information
Mean ± SD/Frequency, n (%)
p-value*
Total 
(N = 351)
Headminder 
participants 
(N = 125)
CANTAB 
participants 
(N = 122)
Age (years) 51.2 ± 9.1 49.9 ± 9.2 50.8 ± 8.6 0.40
Ethnicity
Chinese 285 (81.2) 100 (80.0) 99 (81.1)
0.86
Malay 34 (9.7) 13 (10.4) 10 (8.2)
Indian 20 (5.7) 7 (5.6) 6 (4.9)
Others 12 (3.4) 5 (4.0) 7 (5.7)
Education
No education 4 (1.1) 0 (0.0) 0 (0.0)
0.92
Grade school 48 (13.7) 13 (10.4) 12 (9.8)
High school 160 (45.6) 53 (42.4) 55 (45.1)
Pre-university college 72 (20.5) 32 (25.6) 27 (22.1)
College/graduate degree 67 (19.1) 27 (21.6) 28 (23.0)
Menopausal Pre-menopausal 176 (50.1) 66 (52.8) 67 (54.9)
0.74
status Post-menopausal 175 (49.9) 59 (47.2) 55 (45.1)
Cancer stage
Stage I 61 (17.4) 30 (24.0) 19 (15.6)
0.94Stage II 210 (59.8) 62 (49.6) 80 (65.6)
Stage III 80 (22.8) 33 (26.4) 23 (18.9)
ECOG status
0 336 (95.6) 117 (93.6) 119 (97.5)
0.13
1 15 (4.3) 8 (6.4) 3 (2.5)
Chemoregime
Anthracycline-based 227 (64.7) 78 (62.4) 79 (64.8)
0.7
Taxane-based 124 (35.3) 47 (37.6) 43 (35.2)
Behavioral symptoms
Baseline fatigue (BFI total score) 1.6 ± 1.8 1.6 ± 1.7 1.8 ± 1.9 0.36
Baseline anxiety (BAI total score) 6.8 ± 6.7 6.7 ± 5.8 7.4 ± 8.3 0.49
Baseline insomnia score 22.7 ± 26.7 22.7 ± 26.0 24.3 ± 28.4 0.63
Table 1. Demographic and clinical characteristics of the total cohort, Headminder participants and CANTAB 
participants. *Comparison between Headminder and CANTAB participants.
Number of patients, n (%)
Overall* At T2 At T3
Impairment in subjective test measures (FACT-Cog), N = 351
Overall cognition 117 (33.3) 70 (19.9) 93 (26.5)
Mental acuity 103 (29.3) 57 (16.2) 84 (23.9)
Concentration 98 (27.9) 57 (16.2) 76 (21.7)
Multitasking 98 (27.9) 59 (16.8) 78 (22.2)
Verbal fluency 74 (21.1) 42 (12.0) 59 (16.8)
Memory 73 (20.8) 41 (11.7) 56 (16.0)
Functional interference 68 (19.4) 33 (9.4) 52 (14.8)
Impairment in objective test measures (Headminder), N = 125
Learning and memory 21 (16.8) 12 (9.6) 16 (12.8)
Attention 20 (16.0) 14 (11.2) 9 (7.2)
Processing speed 13 (10.4) 7 (5.6) 7 (5.6)
Response speed 9 (7.2) 6 (4.8) 3 (2.4)
Impairment in objective test measures (CANTAB), N = 122
Processing speed 45 (36.9) 26 (21.3) 35 (28.7)
Attention 32 (26.2) 18 (14.8) 25 (20.5)
Response speed 37 (30.3) 21 (17.2) 23 (18.9)
Learning and memory 17 (13.9) 12 (9.8) 8 (6.6)
Table 2. Proportion of patients with CACI. *Impairment at either T2, T3 or both time points.
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Genotyping and allele frequencies. All patients included in the final analysis were successfully geno-
typed for DNMT1 SNPs. A total of 215 (61.3%) patients were homozygous for the major allele (GG) of rs2162560 
and 17 patients (4.8%) were homozygous for the minor allele (Table 3). A total of 153 patients (21.8%) were carri-
ers of the A allele. There was no significant difference between the genotype frequencies between patients assessed 
by Headminder and CANTAB (P = 0.55).
Association of DNMT1 SNP rs2162560 with CACI. Analysis of self-perceived cognitive impairment 
revealed that patients with the A allele of DNMT1 rs2162560 had significantly lower odds of cognitive impair-
ment in the concentration ability domain (OR = 0.45, 95% CI: 0.25–0.82, P = 0.01). Similarly, the presence of the 
A allele was also associated with lower odds of impairment in the functional interference domain (OR = 0.48, 
95% CI: 0.24–0.95, P = 0.03) (Table 4). There was no statistically significant association between the DNMT1 
rs2162560 genotype and other cognitive domains. An analysis performed using a general genetic model yielded 
similar results (Supplementary Table S4).
No association between the DNMT1 rs2162560 genotype and objective cognitive impairment assessed was 
observed (Table 5).
Subgroup analysis. A subgroup analysis was carried out with patients below the median age of the cohort, 
which was ≤51 years of age (N = 177). The results revealed that the DNMT1 rs2162560 A allele was protective 
against deteriorations in the memory domain (OR = 0.26, 95% CI: 0.09–0.71, P = 0.01), concentration domain 
(OR = 0.30, 95% CI: 0.12–0.74, P = 0.01), and mental acuity domain (OR = 0.42, 95% CI = 0.18–0.96, P = 0.04) 
of the FACT-Cog (Supplementary Table S5).
Discussion
In this study, we found an association between the DNMT1 rs2162560 SNP and self-perceived cognitive impair-
ment in breast cancer patients; carriers of the A allele experienced lower odds of self-reported cognitive decline 
in two cognitive domains: concentration and functional interference. These findings are relevant and novel as no 
known associations between SNPs in DNMT1 and CACI have been described in the literature. A study involving 
Genotype/
Allele
Frequencies, n (%)
Total
Headminder 
participants
CANTAB 
participants
(N = 351) (N = 125) (N = 122)
GG 215 (61.3) 80 (64.0) 70 (57.4)
GA 119 (33.9) 39 (31.2) 46 (37.7)
AA 17 (4.8) 6 (4.8) 6 (4.9)
G allele 549 (78.2) 199 (79.6) 186 (76.2)
A allele 153 (21.8) 51 (20.4) 58 (23.8)
Table 3. Genotype and allele frequencies of DNMT1 rs2162560.
Fact-cog domain
Odds 
ratio p value 95% CI
Overall cognition 0.65 0.13 0.38–1.13
Mental acuity 0.70 0.22 0.39–1.24
Concentration 0.45 0.01* 0.25–0.82
Multi-tasking 0.99 0.97 0.56–1.73
Verbal fluency 0.68 0.23 0.37–1.27
Memory 0.69 0.23 0.37–1.27
Functional interference 0.48 0.03* 0.24–0.95
Table 4. Association between DNMT1 rs2162650 A allele and subjective CACI, N = 351. *P < 0.05.
Cognitive domain
Headminder participants (N = 125) CANTAB participants (N = 122)
Odds 
ratio p value 95% CI
Odds 
ratio p value 95% CI
Attention 0.82 0.72 0.28–2.44 0.97 0.95 0.40–2.37
Learning and memory 1.35 0.60 0.45–4.05 2.79 0.11 0.80–9.69
Processing speed 1.67 0.43 0.46–6.06 1.50 0.36 0.63–3.56
Response speed 1.42 0.65 0.32–6.42 1.33 0.51 0.58–3.06
Table 5. Association between DNMT1 rs2162650 A allele and objective CACI assessed by Headminder and 
CANTAB.
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210 Brazilian Caucasian participants found no association between DNMT1 rs2162560 and Alzheimer’s disease19. 
A study on 632 South Indians reported a significant association between schizophrenia and DNMT1 rs2114724 
and rs2228611, but no association was found with DNMT1 rs216256020. These results are not necessarily conflict-
ing because cognitive disorders are complex and the mechanisms of disease manifestation in AD, schizophrenia, 
and CACI are very different. Both AD and CACI are associated with oxidative stress but they are propagated by 
different mechanistic pathways32. For example, subjective CACI has been characterized to be exacerbated by 
psychosocial or behavioral conditions including fatigue and anxiety3. In fact, the cognitive symptoms reported 
by patients are likely to be an extension of these conditions. The established association between DNMT1 
SNPs and behavioral disorders could explain why we observed an association between DNMT1 rs2162560 and 
self-perceived cognitive impairment but not other domains of objective cognitive impairment. Furthermore, the 
populations analyzed in these studies may differ in genetic background and response to environmental factors, 
including chemotherapy treatment. DNA methylation is an epigenetic alteration that enables interaction with 
internal and external cues to create long-lasting changes in gene expression and possibly alter their homeostatic 
function and subjective experience33. Hence, the effects of DNMT1 SNPs may vary according to disease state or 
population.
The rs2162560 polymorphism is located in the intronic region of the DNMT1 gene on chromosome 19. 
Although introns are in the non-coding region, they may be involved in functions such as regulating alterna-
tive splicing or enhancing gene expression34. The rs2162560 mutant A allele is suspected to confer an intronic 
enhancer effect, similar to the DNMT1 rs2114724 T allele, which is associated with schizophrenia20. Global meth-
ylation status, as measured by the methylation of surrogate marker LINE-1, is higher in men with at least one 
mutant rs2114724 allele35. Since rs2162560 and rs2114724 were highly correlated in a linkage disequilibrium 
study (coefficient = 0.85, P < 0.001)15, carriers of the rs2162560 polymorphism will likely display increased DNA 
methylation activity. This supports our hypothesis that the A allele of rs2162560 confers a protective effect in cog-
nitive domains such as concentration and memory potentially by increasing methylation activity.
In cancer patients undergoing chemotherapy, both cancer and its treatment have been speculated to trigger 
reprogramming of the genome, resulting in changes to gene expression and neuronal transmission33. A study 
using the TumorGraft mouse model found that global DNA methylation and DNMT1 levels decreased in the 
pre-frontal cortex of mice with triple-negative or progesterone-positive breast cancer TumorGrafts36. The A allele 
polymorphism may change DNMT1 activity to mitigate these adverse effects.
Genome-wide DNA methylation and expression levels of DNMTs in the pre-frontal cortex and hippocampus 
decrease with age and affect learning and memory37. We found that the DNMT1 rs2162560 A allele conferred a 
protective effect against declines in the memory, concentration, and mental acuity domains of the FACT-Cog in 
a younger subgroup of patients under 51 years of age. One possible explanation may be that, while rs2162560 
exerts a protective effect through enhancing DNMT1 function, the decreased amount of DNMT1 in older patients 
diminishes any positive effect. Further studies are needed to elucidate how aging confounds the association 
between DNMT1 polymorphisms and CACI.
This study has multiple strengths, including the pre-treatment and longitudinal assessment of cognitive func-
tion and behavioral symptoms across three time points, adjustment for known clinical confounders of cognition, 
and use of validated tools to evaluate cognition. We have also included both subjective and objective cognitive 
assessments, as recommended by the International Cognition and Cancer Task Force (ICCTF)29. Cognitive pro-
files observed in this study are highly consistent with our previous study where we have presented the existence of 
heterogeneous cognitive trajectories among cancer patients receiving chemotherapy3. As CACI is a multifactorial, 
complex phenotype, the precision of the results could be improved by adjusting for additional clinical, behavioral, 
and environmental factors, along with assessing different aspects of cognitive function. We adjusted for different 
covariates in the regression models (subjective and objective assessments) to ensure that the most clinically rele-
vant variables were represented in the models. However, it remains unknown whether these results are applicable 
to delayed-onset CACI. Another limitation is changing the objective cognition assessment tool mid-study to 
CANTAB since the Headminder system was no longer commercially available. Due to this switch in assessment 
tools and other logistical issues, cognitive assessments were not completed for all participants. It is challenging 
to compare data generated from two different assessment tools, as they may have different sensitivities or subtle 
differences in the cognition functions assessed. This also explains why we observed fewer patients classified as 
impaired by Headminder than CANTAB. Hence, we reported the data obtained from both tools separately and 
did not pool the data. However, we ensured that all neuropsychological tests used were validated for the same 
cognitive domains23,24. We also calibrated the RCI to standardize the measurement of cognitive changes indicated 
by each tool.
conclusions
In conclusion, to the best of our knowledge, this is the first study to evaluate the genetic association between a 
DNMT1 polymorphism and CACI. The A allele of rs2162560 showed a neuroprotective effect in the concentra-
tion and functional interference domains. These findings suggest that subjective CACI in cancer patients, which 
is often exacerbated by behavioral symptoms, is associated with epigenetic processes. Further validation of the 
current findings is required. These future studies should include measurement of plasma methylation levels at 
various time points to correlate the effect of DNMT1 polymorphisms with cognitive function, which will provide 
further insight into the underlying epigenetic process. We could use this knowledge to identify patients who are 
at higher risk of developing CACI post-chemotherapy and provide targeted preventive strategies. Lastly, this 
study also provides the impetus to explore the use of pharmacological agents that target methylation in managing 
CACI.
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